This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Humoral Antibody Kinetics with ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) Vaccine among Indian Healthcare workers: A 6-month Longitudinal Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) Study
Preprint
in English
| medRxiv
| ID: ppmedrxiv-22270182
ABSTRACT
Background and AimsThere is limited data available on longitudinal humoral antibody dynamics following two doses of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) vaccine against SARS-CoV-2 among Indians. MethodsWe conducted a 6-month longitudinal study in vaccinated healthcare workers by serially measuring quantitative anti-spike antibody at 3-weeks, 3-months and 6- months after the completion of second dose. Geometric mean titer (GMT) and linear mixed models were used to assess the dynamics of antibody levels at 6 months. ResultsOf the 481 participants, GMT of anti-spike antibody decreased by 56% at 6- months regardless of demographics and comorbidities in 360 SARS-CoV-2 naive individuals, significantly in hypertensives. Participants with past infection had significantly higher GMT at all time points compared to naive individuals. Among SARS-CoV-2 naive cohorts, a significantly higher GMT was noted amongst the Covishield recipients at all time points, but there was a 44% decline in GMT at 6- month compared to peak titer period. Decline in GMT was insignificant (8%) in Covaxin recipients at 6-month despite a lower GMT at all time points vs. Covishield. There was 5.6-fold decrease in seropositivity rate at 6-month with both vaccines. Participants with type 2 diabetes mellitus have a lower seropositivity rate at all the time points. While seropositivity rate was significantly higher with Covishield vs. Covaxin at all time points except at 6-month where Covaxin recipients had a higher seropositivity, although no difference in seropositivity was noted in propensity-matched analysis. ConclusionsThere is waning humoral antibody response following two doses of either vaccine at six months. HighlightsO_LIWe assessed humoral antibody dynamics following two doses of the two vaccines used in India until 6 months. C_LIO_LIOur study of 481 health care workers showed a significant decrease in the anti-spike antibody at 6-months. C_LIO_LIReduction in antibody was regardless of demographics, comorbidities and the vaccine type. C_LIO_LIT2DM cohorts had lowest seropositivity, while hypertensive had significant antibody decline at 6-month. C_LI
cc_by_nc_nd
Full text:
Available
Collection:
Preprints
Database:
medRxiv
Type of study:
Cohort_studies
/
Observational study
/
Prognostic study
/
Rct
Language:
English
Year:
2022
Document type:
Preprint
